By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tonix Pharmaceuticals, Inc. 

509 Madison Ave.
Suite 306
New York  New York  10022  U.S.A.
Phone: 212-980-9155 Fax: 212-923-5700




Company News
Tonix Pharma (TNXP) Enrolls First Participant In Military-Related PTSD Phase III Trial Of FDA Breakthrough Therapy-Designated TNX-102 SL 3/28/2017 11:26:59 AM
Tonix Pharma (TNXP) Announces 1-For-10 Reverse Stock Split 3/17/2017 8:07:45 AM
Tonix Pharma (TNXP) Receives Notice Of Allowance For New U.S. Patent Covering Composition And Manufacture Of TNX-102 SL 3/14/2017 8:10:03 AM
Tonix Pharma (TNXP) Announces Demonstrated Vaccine Activity In First-Ever Synthesized Chimeric Horsepox Virus 3/2/2017 8:26:35 AM
Tonix Pharma (TNXP) Release: Company Presented Details Of Newly Expanded Product Development Pipeline At 9th Annual Biotech Showcase Conference 1/11/2017 7:00:34 AM
Tonix Pharma (TNXP)’s PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation By The FDA 12/19/2016 7:57:23 AM
Tonix Pharma (TNXP) Presented New Clinical Results From Sub-Group Analysis Of Phase II Atease Study In Military-Related Posttraumatic Stress Disorder (PTSD) 12/8/2016 7:50:14 AM
Tonix Pharma (TNXP) Reports Third Quarter 2016 Financial Results 11/11/2016 7:59:22 AM
Tonix Pharma (TNXP) To Present New Clinical Results From Retrospective Analysis Of Phase II AtEase Study In Military-Related PTSD 11/10/2016 8:50:21 AM
Tonix Pharma (TNXP) Completes $5.2 Million Underwritten Public Offering 11/1/2016 11:07:00 AM